Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Helena Pujol"'
Autor:
Helena Pujol Bech, Clara Rué Cid
Publikováno v:
Revista de la Societat d'Ensenyament i Recerca del Català com a Llengua Estrangera, Iss 1, Pp 90-93 (2020)
L'article presenta una experiència didàctica en llengua catalana com a L2 a l'estranger i dirigida a infants de primària. Recull un projecte teatral dissenyat per dues mestres de l'Escola Catalana de Londres i exposa dificultats trobades en el pro
Externí odkaz:
https://doaj.org/article/f86def145daf44ff9bdd239538fcd574
Autor:
Eulalia Jimenez, Carol Astbury, Muna Albayaty, Ulrika Wählby-Hamrén, Beatriz Seoane, Cristina Villarroel, Helena Pujol, Maria Jesus Bermejo, Ajay Aggarwal, Ioannis Psallidas
Publikováno v:
Respiratory Research, Vol 21, Iss S1, Pp 1-9 (2020)
Abstract Background Navafenterol (AZD8871) is an inhaled long-acting dual-pharmacology muscarinic antagonist/β2-adrenoceptor agonist (MABA) in development for the treatment of obstructive airways diseases. The safety, tolerability, pharmacodynamics,
Externí odkaz:
https://doaj.org/article/5eb0ee5d18dd4886a2482e4d36b7db73
Autor:
Clara Rué Cid, Helena Pujol Bech
Publikováno v:
Revista de la Societat d'Ensenyament i Recerca del Català com a Llengua Estrangera, Iss 1, Pp 90-93 (2020)
L'article presenta una experiència didàctica en llengua catalana com a L2 a l'estranger i dirigida a infants de primària. Recull un projecte teatral dissenyat per dues mestres de l'Escola Catalana de Londres i exposa dificultats trobades en el pro
Autor:
Jonathan Bernstein, Jonathan Matz, Gary Steven, William Greisner, David Cypcar, Arthur Fost, Richard Powell, Chris Smith, Markus Berger, Uwe Berger, Lukas Dirr, Maximilian Bastl, Johannes Bouchal, Helena Pujol, Marietta Krebs, Oliver Armfield, Lawrence DuBuske, Pieter-Jan de Kam
Publikováno v:
Journal of Allergy and Clinical Immunology. 149:AB199
Autor:
Maria-Jesus Bermejo, Cristina Villarroel, Carol Astbury, Helena Pujol, Ajay Aggarwal, Beatriz Seoane, Lali Jimenez, Muna Albayaty
Publikováno v:
Airway Pharmacology and Treatment.
AZD8871 is an inhaled long acting dual muscarinic antagonist/ β 2 adrenoceptor agonist (MABA) under development for the treatment of COPD and asthma. This was an ascending-dose first in man trial, designed to test safety, tolerability, pharmacokinet
Autor:
Carol Astbury, Tim Mant, Meritxell Falques, Eric Massana, Helena Pujol, Gonzalo de Miquel, Marisa Gonzalez
Publikováno v:
Airway Pharmacology and Treatment.
AZD8999 is an inhaled long-acting, dual muscarinic antagonist/β 2 adrenoceptor agonist (MABA) under development for the treatment of COPD and asthma. This was an ascending-dose first in man trial, designed to test safety, tolerability, pharmacokinet
Autor:
Dave Singh, Marisa Gonzalez, Eric Massana, Tim Mant, Helena Pujol, Meritxell Falques, Carol Astbury
Publikováno v:
5.1 Airway Pharmacology and Treatment.
Background AZD8999 (formerly LAS190792) is a novel MABA bronchodilator in development for COPD treatment. Aims and objectives Phase I safety, tolerability, PD & PK study of single doses of AZD8999, in patients with COPD. This investigation formed Par
Autor:
B. Seoane, G de Miquel, Eric Massana, Dave Singh, Jutta Beier, Helena Pujol, Eulalia Jimenez, Sandrine Ruiz, Carol Astbury, Rainard Fuhr
Publikováno v:
Pneumologie. 69
Autor:
Sandrine Ruiz, Dave Singh, Gonzalo de Miquel, Beatriz Seoane, Eric Massana, Anna Ribera, Carol Astbury, Helena Pujol
Publikováno v:
BMC Pulmonary Medicine
Background Long-acting β2-adrenergic agonists (LABAs) are recommended in combination with inhaled corticosteroids (ICSs) for asthma management. Abediterol is a novel, selective, potent, once-daily LABA in development for treatment of asthma and chro
Autor:
Helena Pujol, Beatriz Seoane, Eric Massana, Gonzalo de Miquel, Sandrine Ruiz, Jutta Beier, Rainard Fuhr
Publikováno v:
Pharmacology Research & Perspectives
Abediterol is a once‐daily, long‐acting β 2‐adrenergic agonist in development for the treatment of asthma and chronic obstructive pulmonary disease. We assessed the efficacy, safety, and tolerability of three dose levels of abediterol, given o